Cargando…

Medical Management of Hereditary Optic Neuropathies

Hereditary optic neuropathies are diseases affecting the optic nerve. The most common are mitochondrial hereditary optic neuropathies, i.e., the maternally inherited Leber’s hereditary optic neuropathy (LHON) and dominant optic atrophy (DOA). They both share a mitochondrial pathogenesis that leads t...

Descripción completa

Detalles Bibliográficos
Autores principales: La Morgia, Chiara, Carbonelli, Michele, Barboni, Piero, Sadun, Alfredo Arrigo, Carelli, Valerio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117178/
https://www.ncbi.nlm.nih.gov/pubmed/25132831
http://dx.doi.org/10.3389/fneur.2014.00141
_version_ 1782328678694256640
author La Morgia, Chiara
Carbonelli, Michele
Barboni, Piero
Sadun, Alfredo Arrigo
Carelli, Valerio
author_facet La Morgia, Chiara
Carbonelli, Michele
Barboni, Piero
Sadun, Alfredo Arrigo
Carelli, Valerio
author_sort La Morgia, Chiara
collection PubMed
description Hereditary optic neuropathies are diseases affecting the optic nerve. The most common are mitochondrial hereditary optic neuropathies, i.e., the maternally inherited Leber’s hereditary optic neuropathy (LHON) and dominant optic atrophy (DOA). They both share a mitochondrial pathogenesis that leads to the selective loss of retinal ganglion cells and axons, in particular of the papillo-macular bundle. Typically, LHON is characterized by an acute/subacute loss of central vision associated with impairment of color vision and swelling of retinal nerve fibers followed by optic atrophy. DOA, instead, is characterized by a childhood-onset and slowly progressive loss of central vision, worsening over the years, leading to optic atrophy. The diagnostic workup includes neuro-ophthalmologic evaluation and genetic testing of the three most common mitochondrial DNA mutations affecting complex I (11778/ND4, 3460/ND1, and 14484/ND6) for LHON and sequencing of the nuclear gene OPA1 for DOA. Therapeutic strategies are still limited including agents that bypass the complex I defect and exert an antioxidant effect (idebenone). Further strategies are aimed at stimulating compensatory mitochondrial biogenesis. Gene therapy is also a promising avenue that still needs to be validated.
format Online
Article
Text
id pubmed-4117178
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-41171782014-08-15 Medical Management of Hereditary Optic Neuropathies La Morgia, Chiara Carbonelli, Michele Barboni, Piero Sadun, Alfredo Arrigo Carelli, Valerio Front Neurol Neuroscience Hereditary optic neuropathies are diseases affecting the optic nerve. The most common are mitochondrial hereditary optic neuropathies, i.e., the maternally inherited Leber’s hereditary optic neuropathy (LHON) and dominant optic atrophy (DOA). They both share a mitochondrial pathogenesis that leads to the selective loss of retinal ganglion cells and axons, in particular of the papillo-macular bundle. Typically, LHON is characterized by an acute/subacute loss of central vision associated with impairment of color vision and swelling of retinal nerve fibers followed by optic atrophy. DOA, instead, is characterized by a childhood-onset and slowly progressive loss of central vision, worsening over the years, leading to optic atrophy. The diagnostic workup includes neuro-ophthalmologic evaluation and genetic testing of the three most common mitochondrial DNA mutations affecting complex I (11778/ND4, 3460/ND1, and 14484/ND6) for LHON and sequencing of the nuclear gene OPA1 for DOA. Therapeutic strategies are still limited including agents that bypass the complex I defect and exert an antioxidant effect (idebenone). Further strategies are aimed at stimulating compensatory mitochondrial biogenesis. Gene therapy is also a promising avenue that still needs to be validated. Frontiers Media S.A. 2014-07-31 /pmc/articles/PMC4117178/ /pubmed/25132831 http://dx.doi.org/10.3389/fneur.2014.00141 Text en Copyright © 2014 La Morgia, Carbonelli, Barboni, Sadun and Carelli. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
La Morgia, Chiara
Carbonelli, Michele
Barboni, Piero
Sadun, Alfredo Arrigo
Carelli, Valerio
Medical Management of Hereditary Optic Neuropathies
title Medical Management of Hereditary Optic Neuropathies
title_full Medical Management of Hereditary Optic Neuropathies
title_fullStr Medical Management of Hereditary Optic Neuropathies
title_full_unstemmed Medical Management of Hereditary Optic Neuropathies
title_short Medical Management of Hereditary Optic Neuropathies
title_sort medical management of hereditary optic neuropathies
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117178/
https://www.ncbi.nlm.nih.gov/pubmed/25132831
http://dx.doi.org/10.3389/fneur.2014.00141
work_keys_str_mv AT lamorgiachiara medicalmanagementofhereditaryopticneuropathies
AT carbonellimichele medicalmanagementofhereditaryopticneuropathies
AT barbonipiero medicalmanagementofhereditaryopticneuropathies
AT sadunalfredoarrigo medicalmanagementofhereditaryopticneuropathies
AT carellivalerio medicalmanagementofhereditaryopticneuropathies